These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
28. Modulating luminescence of Tb(3+) with biomolecules for sensing heparin and its contaminant OSCS. Hu Y; Guo W; Ding Y; Cheng H; Wei H Biosens Bioelectron; 2016 Dec; 86():858-863. PubMed ID: 27494809 [TBL] [Abstract][Full Text] [Related]
29. Composition of OSCS-contaminated heparin occurring in 2008 in batches on the German market. Beyer T; Matz M; Brinz D; Rädler O; Wolf B; Norwig J; Baumann K; Alban S; Holzgrabe U Eur J Pharm Sci; 2010 Jul; 40(4):297-304. PubMed ID: 20399266 [TBL] [Abstract][Full Text] [Related]
30. Class modeling analysis of heparin 1H NMR spectral data using the soft independent modeling of class analogy and unequal class modeling techniques. Zang Q; Keire DA; Wood RD; Buhse LF; Moore CM; Nasr M; Al-Hakim A; Trehy ML; Welsh WJ Anal Chem; 2011 Feb; 83(3):1030-9. PubMed ID: 21192734 [TBL] [Abstract][Full Text] [Related]
31. MEN16132, a novel potent and selective nonpeptide kinin B2 receptor antagonist: in vivo activity on bradykinin-induced bronchoconstriction and nasal mucosa microvascular leakage in anesthetized guinea pigs. Valenti C; Cialdai C; Giuliani S; Lecci A; Tramontana M; Meini S; Quartara L; Maggi CA J Pharmacol Exp Ther; 2005 Nov; 315(2):616-23. PubMed ID: 16027229 [TBL] [Abstract][Full Text] [Related]
32. Simple fluorescence assay for quantification of OSCS in heparin. Lühn S; Schiemann S; Alban S Anal Bioanal Chem; 2011 Jan; 399(2):673-80. PubMed ID: 20552175 [TBL] [Abstract][Full Text] [Related]
33. Toward a better understanding of the hemodynamic effects of protamine and heparin interaction. Stefaniszyn HJ; Novick RJ; Salerno TA J Thorac Cardiovasc Surg; 1984 May; 87(5):678-86. PubMed ID: 6717047 [TBL] [Abstract][Full Text] [Related]
34. Effect of Ca2+ on the 1H NMR chemical shift of the methyl signal of oversulphated chondroitin sulphate, a contaminant in heparin. McEwen I; Rundlöf T; Ek M; Hakkarainen B; Carlin G; Arvidsson T J Pharm Biomed Anal; 2009 Apr; 49(3):816-9. PubMed ID: 19179033 [TBL] [Abstract][Full Text] [Related]
35. Analysis of crude heparin by (1)H NMR, capillary electrophoresis, and strong-anion-exchange-HPLC for contamination by over sulfated chondroitin sulfate. Keire DA; Trehy ML; Reepmeyer JC; Kolinski RE; Ye W; Dunn J; Westenberger BJ; Buhse LF J Pharm Biomed Anal; 2010 Mar; 51(4):921-6. PubMed ID: 19959313 [TBL] [Abstract][Full Text] [Related]
36. Review: contaminants in heparin: review of the literature, molecular profiling, and clinical implications. Ramacciotti E; Clark M; Sadeghi N; Hoppensteadt D; Thethi I; Gomes M; Fareed J Clin Appl Thromb Hemost; 2011 Apr; 17(2):126-35. PubMed ID: 21288929 [TBL] [Abstract][Full Text] [Related]
37. Synthesis and detection of N-sulfonated oversulfated chondroitin sulfate in marketplace heparin. Mans DJ; Ye H; Dunn JD; Kolinski RE; Long DS; Phatak NL; Ghasriani H; Buhse LF; Kauffman JF; Keire DA Anal Biochem; 2015 Dec; 490():52-4. PubMed ID: 26278168 [TBL] [Abstract][Full Text] [Related]
38. Effects of FR173657, a non-peptide B2 antagonist, on kinin-induced hypotension, visceral and peripheral oedema formation and bronchoconstriction. Griesbacher T; Legat FJ Br J Pharmacol; 1997 Mar; 120(5):933-9. PubMed ID: 9138701 [TBL] [Abstract][Full Text] [Related]
39. Analysis of cytokine secretion from lymphocytes of patients with hypersensitivity reactions to contaminated heparins. Martin M; Ott H; Merk HF; Sachs B Br J Dermatol; 2011 Jan; 164(1):68-75. PubMed ID: 20854434 [TBL] [Abstract][Full Text] [Related]
40. Fucosylated chondroitin sulfate as a new oral antithrombotic agent. Fonseca RJ; Mourão PA Thromb Haemost; 2006 Dec; 96(6):822-9. PubMed ID: 17139379 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]